Login
Lexicon Pharmaceuticals NASDAQ: LXRX
The orally-delivered small molecule drug candidates under development by Lexicon Pharmaceuticals comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes
| Name | Lexicon Pharmaceuticals |
| Ticker | LXRX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Price | 7.61 |
| 52W Low/High | 1.05 / 8.05 |
| Market cap | 815 M |
| 1Y Total Return |
87.90%
Strong |
| 1Y Volatility |
125.34%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
The orally-delivered small molecule drug candidates under development by Lexicon Pharmaceuticals comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes
Details
| Ticker | LXRX |
| Name | Lexicon Pharmaceuticals |
| ISIN | US5288723027 |
| CUSIP | 528872302 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/20/21
| Close Price | 7.61 |
| 52W Low/High | 1.05 / 8.05 |
| Market cap | 815 M |
| 1Y Total Return |
87.90%
Strong |
| 1Y Volatility |
125.34%
High Risk |
| Beta | 0.97 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -320.4% |
| Cash from Op. / Cur. Liabilities | -1.69 |
| Diluted Earnings / Share | -1.00 |
| ROE | - |
| ROIC | -61.1% |
| Price / Revenue | 27.5 |
| Price / Book | 10.2 |
| Price / CF | -6.7 |
| Current Ratio | 1.5 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.23 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
33
|
330
|
81
|
76
|
188
|
22
|
|
| Gross Profit |
30
|
327
|
78
|
75
|
188
|
22
|
|
| R&D |
193
|
64
|
131
|
136
|
168
|
85
|
|
| EBITDA |
-81
|
183
|
-109
|
-122
|
-14
|
-88
|
|
| Operating Income |
-88
|
176
|
-116
|
-125
|
-17
|
-86
|
|
| Net Income exc. Extra |
-
|
164
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
118
|
117
|
106
|
106
|
104
|
104
|
|
| EPS exc. Extra |
-1.00
|
1.36
|
-1.20
|
-1.17
|
-0.23
|
-0.87
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
179
|
445
|
310
|
329
|
517
|
391
|
|
| Cash, Eq & Invt ShortTerm |
111
|
296
|
187
|
197
|
396
|
256
|
|
| Total Current Assets |
122
|
364
|
198
|
214
|
399
|
289
|
|
| Total Non-Current Assets |
57
|
81
|
112
|
115
|
118
|
102
|
|
| Intangibles |
45
|
65
|
95
|
97
|
98
|
98
|
|
| Total Liabilities |
91
|
280
|
340
|
251
|
332
|
193
|
|
| Total Current Liabilities |
79
|
45
|
69
|
129
|
170
|
52
|
|
| Long Term Debt |
12
|
235
|
271
|
122
|
162
|
141
|
|
| Shareholder equity |
88
|
165
|
-29
|
78
|
185
|
198
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-133
|
111
|
-155
|
-200
|
139
|
-86
|
|
| Depreciation |
4
|
4
|
4
|
3
|
2
|
1
|
|
| Cash from Investing |
227
|
12
|
-25
|
243
|
-162
|
-164
|
|
| Capex |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash from Financing |
-212
|
-2
|
146
|
2
|
0
|
284
|
|
| Stock Issued |
-1
|
-1
|
2
|
4
|
2
|
202
|
|
| Debt (LT) Issued |
-211
|
-1
|
144
|
-2
|
-2
|
82
|
|
| Free Cash Flow |
13
|
186
|
-186
|
138
|
-92
|
-248
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
49.8%
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
63.0%
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
1.5
|
8.1
|
2.9
|
1.7
|
2.3
|
5.6
|
|
| Financial Leverage D/E |
0.23
|
1.49
|
-
|
1.28
|
0.55
|
0.54
|
|
| Return on Capital Avg |
-61.1%
|
80.9%
|
-70.2%
|
-36.0%
|
-5.3%
|
-44.9%
|
|
| Return on Shareholder Equity |
-
|
243.1%
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available